Adial Pharmaceuticals, Inc.

Addiction is a common disease and likely everyone knows someone who has struggled with it in some way. Alcohol use disorder is one of the most common addictions globally, affecting nearly 400 million

The past year has seen an increase in investment in biopharma companies following a couple of lean years, but the sector is not fully out of the woods yet. However, most industry leaders see funding

The European approval process for Eisai Co., Ltd. / Biogen, Inc. ’s Alzheimer’s disease drug Leqembi (lecanemab) has been delayed due to the unprecedented impact from a recent court ruling related to

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making. In December 2023, Scrip